IP Library › Granted Patent US 9,597,407
Granted Patent B2
US 9,597,407 · App. 14/255,858 · Granted Mar 21, 2017

Targeted antimicrobial moieties

Inventors: Randal H. Eckert (Ranch Palos Verdes, CA); Chris Kaplan (Los Angeles, CA); Jian He (Guangzhou, CN); Daniel K. Yarbrough (Ann Arbor, MI); Maxwell Anderson (Sequim, WA); Jee-Hyun Sim (La Habra, CA)
Assignee: C3 JIAN, LLC
A61K47/48246A01N37/46A61K8/64A61K9/0019A61K9/0063A61K9/06A61K38/08A61K38/10A61K38/16A61K41/0009A61K41/0057A61K41/0071A61K47/10A61K47/26A61K47/34A61Q11/00C07K7/06C07K7/08C07K14/001G01N33/569
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,597,407
App. No.
14/255,858
Granted
Mar 21, 2017
Kind
B2
Abstract

This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.

Claims (16)

1. A chimeric construct, said construct comprising:

a targeting peptide comprising the amino acid sequence LATKLKYEKEHKKM (SEQ ID NO:554), where said targeting peptide is attached to an antimicrobial peptide, wherein said targeting peptide is attached to said antimicrobial peptide directly or through a peptide linker and where said chimeric construct is a fusion protein.

2. The chimeric construct of claim 1 , wherein said antimicrobial peptide comprises an amino acid sequence found in Table 4, and/or Table 5, and/or Table 14, and/or Table 15.

3. The chimeric construct of claim 1 , wherein said targeting peptide is linked directly to said antimicrobial peptide.

4. The chimeric construct of claim 1 , wherein said targeting peptide is linked to said antimicrobial peptide via a peptide linker.

5. The chimeric construct of claim 4 , wherein said targeting peptide is attached to said antimicrobial peptide by a peptide linker comprising an amino acid sequence selected from the group consisting of AAA, GGG, GGGG (SEQ ID NO:3212), SGG, GGSGGS (SEQ ID NO:3213), SAT, PYP, PSPSP (SEQ ID NO:3216), ASA, ASASA (SEQ ID NO:3215), KKKK (SEQ ID NO:3217), RRRR (SEQ ID NO:3218), GGGGS (SEQ ID NO:3219), GGGGS GGGGS (SEQ ID NO:3220), GGGGS GGGGS GGGGS (SEQ ID NO:3221), GGGGS GGGGS GGGGS GGGGS (SEQ ID NO:3222), GGGGS GGGGS GGGGS GGGGS GGGGS (SEQ ID NO:3223), and GGGGS GGGGS GGGGS GGGGS GGGGS GGGGS (SEQ ID NO:3224).

6. A pharmaceutical composition comprising a chimeric construct of claim 1 in a pharmaceutically acceptable carrier.

7. A composition comprising a targeting peptide comprising the amino acid sequence LATKLKYEKEHKKM (SEQ ID NO:554), where said targeting peptide is attached to a photosensitizing agent, wherein said photosensitizing agent is selected from the group consisting of a porphyrin, a cyanine, and a phthalocyanine.

8. The chimeric construct of claim 1 , wherein said antimicrobial peptide comprises an antimicrobial peptide selected from the group consisting of FLKFLKKFFKKLKY (SEQ ID NO:1044), KLFKFLRKHLL (SEQ ID NO:1034), and KNLRIIRKGIHIIKKY (SEQ ID NO:3082).

9. The chimeric construct of claim 1 , wherein said construct bears one or more protecting groups.

10. The chimeric construct according to claim 9 , wherein said one or more protecting groups are independently selected from the group consisting of acetyl, amide, 3 to 20 carbon alkyl groups, Fmoc, Tboc, 9-fluoreneacetyl group, 1-fluorenecarboxylic group, 9-florenecarboxylic group, 9-fluorenone-1-carboxylic group, benzyloxycarbonyl, Xanthyl (Xan), Trityl (Trt), 4-methyltrityl (Mtt), 4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr), Mesitylene-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), Tosyl (Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl (MeBzl), 4-methoxybenzyl (MeOBzl), Benzyloxy (BzlO), Benzyl (Bzl), Benzoyl (Bz), 3-nitro-2-pyridinesulphenyl (Npys), 1-(4,4-dimentyl-2,6-diaxocyclohexylidene)ethyl (Dde), 2,6-dichlorobenzyl (2,6-DiCl-Bzl), 2-chlorobenzyloxycarbonyl (2-Cl—Z), 2-bromobenzyloxycarbonyl (2-Br—Z), Benzyloxymethyl (Bom), t-butoxycarbonyl (Boc), cyclohexyloxy (cHxO), t-butoxymethyl (Bum), t-butoxy (tBuO), t-Butyl (tBu), and Trifluoroacetyl (TFA).

11. The chimeric construct of claim 9 , wherein said construct comprises a protecting group at a carboxyl and/or amino terminus.

12. The chimeric construct of claim 11 , wherein a carboxyl terminus is amidated.

13. The chimeric construct of claim 4 , wherein said targeting peptide is attached to said antimicrobial peptide by a peptide linker consisting of an amino acid sequence selected the group consisting of AAA, GGG, GGGG (SEQ ID NO:3212), SGG, GGSGGS (SEQ ID NO:3213), SAT, PYP, PSPSP (SEQ ID NO:3216), ASA, ASASA (SEQ ID NO:3215), KKKK (SEQ ID NO:3217), RRRR (SEQ ID NO:3218), GGGGS (SEQ ID NO:3219), GGGGS GGGGS (SEQ ID NO:3220), GGGGS GGGGS GGGGS (SEQ ID NO:3221), GGGGS GGGGS GGGGS GGGGS (SEQ ID NO:3222), GGGGS GGGGS GGGGS GGGGS GGGGS (SEQ ID NO:3223), and GGGGS GGGGS GGGGS GGGGS GGGGS GGGGS (SEQ ID NO:3224).

14. The chimeric construct of claim 1 , wherein said targeting peptide ranges in length up to about 50 amino acids.

15. The chimeric construct of claim 1 , wherein the amino acid sequence of said targeting peptide consists of the sequence LATKLKYEKEHKKM (SEQ ID NO:554).

Assignments (7)
SECURITY INTEREST Recorded May 20, 2026
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 074715/0208 →
SECURITY INTEREST Recorded Aug 14, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 072025/0567 →
SECURITY INTEREST Recorded Mar 17, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 070532/0979 →
SECURITY INTEREST Recorded Mar 5, 2024
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 066657/0409 →
SECURITY INTEREST Recorded Jul 14, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 064262/0958 →
SECURITY INTEREST Recorded Feb 17, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 062733/0983 →
CHANGE OF NAME Recorded Jul 21, 2017
From: C3 JIAN, INC.
To: C3 JIAN, LLC
Reel/Frame 043302/0385 →
Continuity (6)
Division 12683160 · Jan 6, 2010
Provisional Application 61142830 · Jan 6, 2009
Provisional Application 61151445 · Feb 10, 2009
Provisional Application 61243905 · Sep 18, 2009
Provisional Application 61243930 · Sep 18, 2009
Related Publication 20140349917A1 · Nov 27, 2014